

RSV Vaccine

- On June 29, 2023, the CDC endorsed the use of a new vaccine, the Respiratory Syncytial Virus (RSV) produced by GSK and Pfizer for people ages 60 and older.
- Per the CDC, adults at the highest risk for severe RSV illness are older adults, adults with chronic heart or lung disease, adults with weakened immune systems, and adults living in nursing homes or long-term care facilities. It is estimated that RSV causes approx. 60,000 – 160,000 hospitalizations and 6,000 – 10,000 deaths each year among older adults.
- Individuals may receive a single dose of the vaccine or more depending on what their healthcare provider deems appropriate.
- Average Wholesale Price (AWP) of the vaccine is expected to be \$300-\$350 per vaccine.
- Cost for Fund would follow the same structure as all other vaccines: AWP minus the 30-day brand discount (20%) plus a \$20 administration fee plus the dispensing fee (\$0.30). This translates into an approx. plan cost of \$280 per vaccine.
- Cost for the member would be \$0.